A Research Study to Determine Levels of Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/7/2015 |
| Start Date: | March 2010 |
| End Date: | March 2014 |
Modulation of Thrombospondin-1 and Pigment Epithelium Derived Factor Levels in Vitreous Fluid and Plasma of Patients With Diabetes
You are being asked to be in a research study to determine blood levels and vitreous levels
of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF).
These compounds exists naturally in your body.
of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF).
These compounds exists naturally in your body.
The hypothesis tested here is that diabetic patients that express the higher molecular
weight pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1)
level and, as a result, are at a greater risk for the development of more severe diabetic
retinopathy.
weight pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1)
level and, as a result, are at a greater risk for the development of more severe diabetic
retinopathy.
Inclusion Criteria:
- Ability to provide written informed consent and comply with study assessments for the
full duration of the study
- Diabetes Mellitus
- Undergoing pars plana vitrectomy for any reason
Exclusion Criteria:
- Use of any anti-VEGF (vascular endothelial growth factor ) medications
We found this trial at
1
site
Click here to add this to my saved trials
